Geode Capital Management LLC lifted its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 2.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,883,199 shares of the biotechnology company's stock after purchasing an additional 51,946 shares during the period. Geode Capital Management LLC owned about 2.22% of Anavex Life Sciences worth $10,699,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC raised its stake in Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after buying an additional 64,101 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company's stock worth $3,783,000 after acquiring an additional 14,892 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company's stock worth $1,968,000 after purchasing an additional 386,537 shares during the last quarter. Nwam LLC acquired a new position in Anavex Life Sciences in the third quarter valued at approximately $5,172,000. Finally, Deerfield Management Company L.P. Series C purchased a new position in Anavex Life Sciences in the second quarter valued at approximately $346,000. Institutional investors and hedge funds own 31.55% of the company's stock.
AVXL opened at $10.74 on Wednesday. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44. The business's 50 day moving average is $8.40 and its two-hundred day moving average is $6.51. The firm has a market cap of $910.92 million, a price-to-earnings ratio of -21.48 and a beta of 0.73.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. Equities analysts expect that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.
Several analysts have recently weighed in on AVXL shares. D. Boral Capital restated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, December 23rd. HC Wainwright boosted their price target on shares of Anavex Life Sciences from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, December 26th.
Get Our Latest Stock Report on Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.